Similarly, our results showed that UBE2C was highly expressed in the tumor tissues of OSCC patients and that a high expression level of UBE2C was associated with shorter DSS in TSCC patients having poor cell differentiation, lymph node metastasis and postoperative radiation therapy, indicating that UBE2C might be a potential diagnostic and prognostic biomarker in OSCC patients, especially in TSCC patients with certain clinicopathological outcomes. This evidence concerns the gene UBE2C and metastatic malignant neoplasm in the lymph nodes.